Markus Zeitlinger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/239300/publications.pdf

Version: 2024-02-01

124 papers 2,705 citations

257450 24 h-index 223800 46 g-index

126 all docs

126 docs citations

times ranked

126

3499 citing authors

#	Article	IF	CITATIONS
1	Comparison of non-invasive Staphylococcus aureus sampling methods on lesional skin in patients with atopic dermatitis. European Journal of Clinical Microbiology and Infectious Diseases, 2022, 41, 245-252.	2.9	6
2	Anticoagulant Treatment Regimens in Patients With Covidâ€19: A Metaâ€Analysis. Clinical Pharmacology and Therapeutics, 2022, 111, 614-623.	4.7	20
3	A versatile high-performance LC-MS/MS assay for the quantification of voriconazole and its N-oxide metabolite in small sample volumes of multiple human matrices for biomedical applications. Journal of Pharmaceutical and Biomedical Analysis, 2022, 210, 114551.	2.8	4
4	Influence of tedizolid on the cytokine response to the endotoxin challenge in healthy volunteers: a cross-over trial. Journal of Antimicrobial Chemotherapy, 2022, 77, 1424-1431.	3.0	3
5	Microdosing as a Potential Tool to Enhance Clinical Development of Novel Antibiotics: A Tissue and Plasma PK Feasibility Study with Ciprofloxacin. Clinical Pharmacokinetics, 2022, , 1.	3.5	5
6	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. Annals of the Rheumatic Diseases, 2022, 81, 687-694.	0.9	43
7	Diclofenac in vitro microdialysis study comparing different experimental setâ€ups to improve quantitative recovery. Basic and Clinical Pharmacology and Toxicology, 2022, , .	2.5	3
8	Convalescent Plasma Treatment in Patients with Covid-19: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2022, 13, 817829.	4.8	23
9	Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review. Clinical Pharmacokinetics, 2022, 61, 593-617.	3.5	14
10	Comparison of Antimycotic Activity of Originator and Generics of Voriconazole and Anidulafungin against Clinical Isolates of Candida albicans and Candida glabrata. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /O	ver tos k 10) Tf 捡 0 377 Td
11	Macrolide Treatment Failure due to Drug–Drug Interactions: Real-World Evidence to Evaluate a Pharmacological Hypothesis. Pharmaceutics, 2022, 14, 704.	4.5	O
12	Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients. Clinical Pharmacokinetics, 2022, 61, 655-672.	3.5	4
13	A Selective Screening Strategy Performed in Pre-School Children and Siblings to Detect Familial Hypercholesterolemia. Children, 2022, 9, 590.	1.5	2
14	Topical niclosamide (ATx201) reduces <i>Staphylococcus aureus</i> colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, doubleâ€blind, placeboâ€controlled Phase 2 trial. Clinical and Translational Medicine, 2022, 12, e790.	4.0	15
15	Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue. Antimicrobial Agents and Chemotherapy, 2022, 66, .	3.2	4
16	A strength and neuromuscular exercise programme did not improve body composition, nutrition and psychological status in children with obesity. Acta Paediatrica, International Journal of Paediatrics, 2021, 110, 288-289.	1.5	1
17	Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infectious Diseases, The, 2021, 21, 213-225.	9.1	255
18	Remdesivir for COVID-19 in Europe: will it provide value for money?. Lancet Respiratory Medicine, the, 2021, 9, 127-128.	10.7	14

#	Article	IF	CITATIONS
19	Which Analysis Approach Is Adequate to Leverage Clinical Microdialysis Data? A Quantitative Comparison to Investigate Exposure and Reponse Exemplified by Levofloxacin. Pharmaceutical Research, 2021, 38, 381-395.	3.5	7
20	Detrimental effects of intrahospital transport on cerebral metabolism in patients suffering severe aneurysmal subarachnoid hemorrhage. Journal of Neurosurgery, 2021, , 1-8.	1.6	8
21	Comparison of Bioelectrical Impedance-Based Methods on Body Composition in Young Patients with Obesity. Children, 2021, 8, 295.	1.5	4
22	Pharmacological and clinical profile of cefiderocol, a siderophore cephalosporin against gram-negative pathogens. Expert Review of Clinical Pharmacology, 2021, 14, 777-791.	3.1	4
23	A phase I study assessing the safety, tolerability, immunogenicity, and low-density lipoprotein cholesterol-lowering activity of immunotherapeutics targeting PCSK9. European Journal of Clinical Pharmacology, 2021, 77, 1473-1484.	1.9	32
24	Bio-Distribution and Pharmacokinetics of Topically Administered \hat{I}^3 -Cyclodextrin Based Eye Drops in Rabbits. Pharmaceuticals, 2021, 14, 480.	3.8	8
25	Protein binding of clindamycin <i>in vivo</i> by means of intravascular microdialysis in healthy volunteers. Journal of Antimicrobial Chemotherapy, 2021, 76, 2106-2113.	3.0	5
26	Inhaled budesonide for early treatment of COVID-19. Lancet Respiratory Medicine, the, 2021, 9, e59.	10.7	2
27	Perioperative administration of cefazolin and metronidazole in obese and non-obese patients: a pharmacokinetic study in plasma and interstitial fluid. Journal of Antimicrobial Chemotherapy, 2021, 76, 2114-2120.	3.0	10
28	Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines. Clinical Microbiology and Infection, 2021, 27, 1529-1530.	6.0	2
29	ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the ABCG2 Single Nucleotide Polymorphism Q141K (c.421C> A) May Lead to Increased Drug Exposure. Frontiers in Pharmacology, 2021, 12, 698966.	3.5	6
30	Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis. Frontiers in Medicine, 2021, 8, 712511.	2.6	7
31	Meropenem concentrations in brain tissue of neurointensive care patients exceed CSF levels. Journal of Antimicrobial Chemotherapy, 2021, 76, 2914-2922.	3.0	9
32	Microdialysis sampling to monitor target-site vancomycin concentrations in septic infants: a feasible way to close the knowledge gap. International Journal of Antimicrobial Agents, 2021, 58, 106405.	2.5	6
33	Quantitative analysis of human brain microdialysate for target site pharmacokinetics of major anesthetics ketamine, midazolam and propofol. Journal of Pharmaceutical and Biomedical Analysis, 2021, 205, 114289.	2.8	2
34	Human Biodistribution and Radiation Dosimetry of the P-Glycoprotein Radiotracer [11C]Metoclopramide. Molecular Imaging and Biology, 2021, 23, 180-185.	2.6	0
35	Impaired Clearance From the Brain Increases the Brain Exposure to Metoclopramide in Elderly Subjects. Clinical Pharmacology and Therapeutics, 2021, 109, 754-761.	4.7	13
36	Precision reimbursement for precision medicine: using real world evidence to evolve from trialâ€andâ€project to trackâ€andâ€pay to learnâ€andâ€predict Clinical Pharmacology and Therapeutics, 2021,	, 4.7	5

#	Article	IF	CITATIONS
37	Predicting Antimicrobial Activity at the Target Site: Pharmacokinetic/Pharmacodynamic Indices versus Time–Kill Approaches. Antibiotics, 2021, 10, 1485.	3.7	7
38	Impact of different antimycotics on cytokine levels in an in vitro aspergillosis model in human whole blood. Infection, 2020, 48, 65-73.	4.7	6
39	Early Antibiotic Prophylaxis Prior to Bypass Surgery Improves Tissue Penetration. Thoracic and Cardiovascular Surgeon, 2020, 68, 669-673.	1.0	2
40	Impact of thrombocytes, on bacterial growth and antimicrobial activity of selected antibiotics. European Journal of Clinical Microbiology and Infectious Diseases, 2020, 39, 593-597.	2.9	4
41	Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [11C]Tariquidar and PET in Humans and Mice. Molecular Pharmaceutics, 2020, 17, 316-326.	4.6	15
42	Low pH reduces the activity of ceftolozane/tazobactam in human urine, but confirms current breakpoints for urinary tract infections. Journal of Antimicrobial Chemotherapy, 2020, 75, 593-599.	3.0	5
43	Human diamine oxidase is readily released from activated neutrophils ex vivo and in vivo but is rarely elevated in bacteremic patients. International Journal of Immunopathology and Pharmacology, 2020, 34, 205873842095494.	2.1	0
44	Pharmacokinetics/Pharmacodynamics of Antiviral Agents Used to Treat SARS-CoV-2 and Their Potential Interaction with Drugs and Other Supportive Measures: A Comprehensive Review by the PK/PD of Anti-Infectives Study Group of the European Society of Antimicrobial Agents. Clinical Pharmacokinetics, 2020, 59, 1195-1216.	3 . 5	28
45	Clinical Pharmacokinetics of Fosfomycin after Continuous Infusion Compared with Intermittent Infusion: a Randomized Crossover Study in Healthy Volunteers. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	9
46	Use of Supplemented or Human Material to Simulate PD Behavior of Antibiotics at the Target Site In Vitro. Pharmaceutics, 2020, 12, 773.	4.5	8
47	Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey. Critical Care, 2020, 24, 516.	5.8	292
48	Single-dose pharmacokinetics of temocillin in plasma and soft tissues of healthy volunteers after intravenous and subcutaneous administration: a randomized crossover microdialysis trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 2650-2656.	3.0	9
49	Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#. Intensive Care Medicine, 2020, 46, 1127-1153.	8.2	504
50	Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents. Clinical Pharmacokinetics, 2020, 59, 827-847.	3.5	6
51	Compatibility of aztreonam in four commercial peritoneal dialysis fluids. Scientific Reports, 2020, 10, 1788.	3.3	4
52	Determination of free clindamycin, flucloxacillin or tedizolid in plasma: Pay attention to physiological conditions when using ultrafiltration. Biomedical Chromatography, 2020, 34, e4820.	1.7	21
53	Preclinical Pharmacokinetic/Pharmacodynamic Studies and Clinical Trials in the Drug Development Process of EMA-Approved Antibacterial Agents: A Review. Clinical Pharmacokinetics, 2020, 59, 1071-1084.	3. 5	17
54	From St. John's wort to tomato and from Rhodiola to cranberry. Wiener Klinische Wochenschrift, 2020, 132, 253-259.	1.9	3

#	Article	IF	CITATIONS
55	Brain Exposure to Piperacillin in Acute Hemorrhagic Stroke Patients Assessed by Cerebral Microdialysis and Population Pharmacokinetics. Neurocritical Care, 2020, 33, 740-748.	2.4	9
56	Linezolid Concentrations in Plasma and Subcutaneous Tissue are Reduced in Obese Patients, Resulting in a Higher Risk of Underdosing in Critically Ill Patients: A Controlled Clinical Pharmacokinetic Study. Journal of Clinical Medicine, 2020, 9, 1067.	2.4	13
57	Meropenem Plasma and Interstitial Soft Tissue Concentrations in Obese and Nonobese Patients—A Controlled Clinical Trial. Antibiotics, 2020, 9, 931.	3.7	14
58	Repeated determination of moxifloxacin concentrations in interstitial space fluid of muscle and subcutis in septic patients. Journal of Antimicrobial Chemotherapy, 2019, 74, 2681-2689.	3.0	3
59	A pragmatic trial in bone and joint infection. Lancet Infectious Diseases, The, 2019, 19, 804-805.	9.1	4
60	Prospective evaluation of the performance of [68Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2169-2177.	6.4	30
61	Impact of erythrocytes on bacterial growth and antimicrobial activity of selected antibiotics. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 485-495.	2.9	7
62	Dexamethasone as an adjuvant for peripheral nerve blockade: a randomised, triple-blinded crossover study in volunteers. British Journal of Anaesthesia, 2019, 122, 525-531.	3.4	55
63	The European Association for Clinical Pharmacology and Therapeutics—25Âyears' young and going strong. European Journal of Clinical Pharmacology, 2019, 75, 743-750.	1.9	11
64	A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure. Naunyn-Schmiedeberg's Archives of Pharmacology, 2019, 392, 1097-1106.	3.0	5
65	Comment on "Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients― Clinical Pharmacokinetics, 2019, 58, 981-982.	3.5	0
66	Plasma and tissue pharmacokinetics of fosfomycin in morbidly obese and non-obese surgical patients: a controlled clinical trial. Journal of Antimicrobial Chemotherapy, 2019, 74, 2335-2340.	3.0	15
67	Towards Improved Pharmacokinetic Models for the Analysis of Transporter-Mediated Hepatic Disposition of Drug Molecules with Positron Emission Tomography. AAPS Journal, 2019, 21, 61.	4.4	14
68	Compatibility of ciprofloxacin with commercial peritoneal dialysis solutions. Scientific Reports, 2019, 9, 6512.	3.3	6
69	Clinically relevant body composition methods for obese pediatric patients. BMC Pediatrics, 2019, 19, 84.	1.7	16
70	High voriconazole target-site exposure after approved sequence dosing due to nonlinear pharmacokinetics assessed by long-term microdialysis. European Journal of Pharmaceutical Sciences, 2019, 131, 218-229.	4.0	12
71	In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid. Infection, 2019, 47, 565-570.	4.7	7
72	Impact of P-Glycoprotein Function on the Brain Kinetics of the Weak Substrate ¹¹ C-Metoclopramide Assessed with PET Imaging in Humans. Journal of Nuclear Medicine, 2019, 60, 985-991.	5.0	38

#	Article	IF	CITATIONS
73	A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood–Brain Barrier. Journal of Nuclear Medicine, 2019, 60, 486-491.	5.0	25
74	Determination of total and free ceftolozane and tazobactam in human plasma and interstitial fluid by HPLC-UV. Journal of Pharmaceutical and Biomedical Analysis, 2019, 163, 34-38.	2.8	19
75	Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography. EJNMMI Research, 2019, 9, 110.	2.5	2
76	Pharmacokinetics of the P-gp Inhibitor Tariquidar in Rats After Intravenous, Oral, and Intraperitoneal Administration. European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43, 599-606.	1.6	18
77	Clinical Pharmacokinetics and Pharmacodynamics of Telavancin Compared with the Other Glycopeptides. Clinical Pharmacokinetics, 2018, 57, 797-816.	3.5	17
78	Extended infusionâ€"putting the benefit into context. Lancet Infectious Diseases, The, 2018, 18, 380-381.	9.1	1
79	Influence of different peritoneal dialysis fluids on the in vitro activity of fosfomycin against Escherichia coli, Staphylococcus aureus, Staphylococcus epidermidis, and Pseudomonas aeruginosa. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 1091-1098.	2.9	6
80	Influence of OATPs on Hepatic Disposition of Erlotinib Measured With Positron Emission Tomography. Clinical Pharmacology and Therapeutics, 2018, 104, 139-147.	4.7	43
81	Compatibility of linezolid with commercial peritoneal dialysis solutions. American Journal of Health-System Pharmacy, 2018, 75, 1467-1477.	1.0	3
82	Target site pharmacokinetics of doxycycline for rosacea in healthy volunteers is independent of the food effect. British Journal of Clinical Pharmacology, 2018, 84, 2625-2633.	2.4	9
83	Lack of dermal penetration of topically applied gentamicin as pharmacokinetic evidence indicating insufficient efficacy. Journal of Antimicrobial Chemotherapy, 2018, 73, 2823-2829.	3.0	7
84	Comment on: Evaluation of cefazolin antimicrobial prophylaxis during cardiac surgery with cardiopulmonary bypass. Journal of Antimicrobial Chemotherapy, 2018, 73, 2587-2588.	3.0	2
85	Vaccines Targeting PCSK9: A Promising Alternative to Passive Immunization with Monoclonal Antibodies in the Management of Hyperlipidaemia?. Drugs, 2018, 78, 799-808.	10.9	15
86	Effect of Pâ€glycoprotein inhibition at the blood–brain barrier on brain distribution of (⟨i⟩R⟨/i⟩)â€[⟨sup⟩11⟨/sup⟩C]verapamil in elderly ⟨i⟩vs.⟨/i⟩ young subjects. British Journal of Clinical Pharmacology, 2017, 83, 1991-1999.	2.4	28
87	A Prediction Method for P-glycoprotein–Mediated Drug–Drug Interactions at the Human Blood–Brain Barrier From Blood Concentration–Time Profiles, Validated With PET Data. Journal of Pharmaceutical Sciences, 2017, 106, 2780-2786.	3.3	4
88	Human Bile Reduces Antimicrobial Activity of Selected Antibiotics against Enterococcus faecalis and Escherichia coli <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	11
89	Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs inÂHumans. Gastroenterology, 2017, 152, 980-982.e3.	1.3	57
90	Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens. European Journal of Clinical Pharmacology, 2017, 73, 1609-1613.	1.9	13

#	Article	IF	Citations
91	Intravenous Fluid Challenge Decreases Intracellular Volume: A Bioimpedance Spectroscopy-Based Crossover Study in Healthy Volunteers. Scientific Reports, 2017, 7, 9644.	3.3	8
92	Assessment of P-Glycoprotein Transport Activity at the Human Blood–Retina Barrier with (<i>R</i>)â€ ¹¹ C-Verapamil PET. Journal of Nuclear Medicine, 2017, 58, 678-681.	5.0	23
93	Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically III Patients. Clinical Pharmacokinetics, 2017, 56, 617-633.	3.5	47
94	Compatibility of Meropenem with Different Commercial Peritoneal Dialysis Solutions. Peritoneal Dialysis International, 2017, 37, 51-55.	2.3	5
95	Colistin dampens fibrinolysis and endothelial activation during endotoxaemia. Thrombosis and Haemostasis, 2017, 117, 1714-1721.	3.4	11
96	The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. Cell Death and Disease, 2017, 8, e3135-e3135.	6.3	34
97	Decreased protein binding of moxifloxacin in patients with sepsis?. GMS Infectious Diseases, 2017, 5, Doc03.	0.8	2
98	Single- and Repeated-Dose Pharmacokinetics of Ceftaroline in Plasma and Soft Tissues of Healthy Volunteers for Two Different Dosing Regimens of Ceftaroline Fosamil. Antimicrobial Agents and Chemotherapy, 2016, 60, 3617-3625.	3.2	34
99	An Exploratory Microdialysis Study to Assess the Ocular Pharmacokinetics of Ciprofloxacin Eye Drops in Rabbits. Journal of Ocular Pharmacology and Therapeutics, 2016, 32, 390-395.	1.4	4
100	Influence of Different Peritoneal Dialysis Fluids on theIn VitroActivity of Cefepime, Ciprofloxacin, Ertapenem, Meropenem and Tobramycin againstEscherichia Coli. Peritoneal Dialysis International, 2016, 36, 662-668.	2.3	8
101	Whole-Body Distribution and Radiation Dosimetry of ¹¹ C-Elacridar and ¹¹ C-Tariquidar in Humans. Journal of Nuclear Medicine, 2016, 57, 1265-1268.	5.0	11
102	Feasibility and pharmacokinetics of caudal blockade in children and adolescents with 30–50 kg of body weight. Paediatric Anaesthesia, 2016, 26, 1053-1059.	1.1	15
103	Tissue pharmacokinetics of telavancin in healthy volunteers: a microdialysis study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3179-3184.	3.0	12
104	Platelet activation at the onset of human endotoxemia is undetectable <i>in vivo</i> . Platelets, 2016, 27, 479-483.	2.3	26
105	Cerebral and Peripheral Metabolism to Predict Successful Reperfusion After Cardiac Arrest in Rats: A Microdialysis Study. Neurocritical Care, 2016, 24, 283-293.	2.4	16
106	An Open, Randomized, Single-Center, Crossover Pharmacokinetic Study of Meropenem after Intraperitoneal and Intravenous Administration in Patients Receiving Automated Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy, 2016, 60, 2790-2797.	3.2	14
107	Pharmacokinetic Aspects of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors. Clinical Pharmacokinetics, 2016, 55, 47-77.	3.5	11
108	Microdialysis Assessment of Cerebral Perfusion during Cardiac Arrest, Extracorporeal Life Support and Cardiopulmonary Resuscitation in Rats – A Pilot Trial. PLoS ONE, 2016, 11, e0155303.	2.5	13

#	Article	IF	CITATIONS
109	Approaching Complete Inhibition of P-Glycoprotein at the Human Blood–Brain Barrier: An (<i>R</i>)-[¹¹ C]Verapamil PET Study. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 743-746.	4.3	74
110	Cefazolin and linezolid penetration into sternal cancellous bone during coronary artery bypass grafting. European Journal of Cardio-thoracic Surgery, 2015, 48, 758-764.	1.4	13
111	Iontophoresis driven concentrations of topically administered diclofenac in skeletal muscle and blood of healthy subjects. European Journal of Clinical Pharmacology, 2015, 71, 1359-1364.	1.9	12
112	Development of a Population Pharmacokinetic Model Characterizing the Tissue Distribution of Azithromycin in Healthy Subjects. Antimicrobial Agents and Chemotherapy, 2014, 58, 6675-6684.	3.2	29
113	Safety and Immunogenicity of a Vero Cell Culture-Derived Whole-Virus H5N1 Influenza Vaccine in Chronically III and Immunocompromised Patients. Vaccine Journal, 2014, 21, 867-876.	3.1	11
114	In vivo P-glycoprotein function before and after epilepsy surgery. Neurology, 2014, 83, 1326-1331.	1.1	37
115	A Novel Multivalent OspA Vaccine against Lyme Borreliosis Is Safe and Immunogenic in an Adult Population Previously Infected with Borrelia burgdorferi Sensu Lato. Vaccine Journal, 2014, 21, 1490-1499.	3.1	36
116	Reply. Annals of Thoracic Surgery, 2013, 96, 1528-1529.	1.3	0
117	An exploratory microdialysis study investigating the effect of repeated application of a diclofenac epolamine medicated plaster on prostaglandin concentrations in skeletal muscle after standardized physical exercise. British Journal of Clinical Pharmacology, 2013, 76, 880-887.	2.4	4
118	Methods to measure target site penetration of antibiotics in critically ill patients. Current Clinical Pharmacology, 2013, 8, 46-58.	0.6	5
119	Pharmacokinetics of a new diclofenac sodium formulation developed for subcutaneous and intramuscular administration. International Journal of Clinical Pharmacology and Therapeutics, 2012, 50, 383-390.	0.6	25
120	Cerebrospinal fluid impairs antimicrobial activity of fosfomycin in vitro-authors' response. Journal of Antimicrobial Chemotherapy, 2010, 65, 2059-2060.	3.0	0
121	Ketolides – The Modern Relatives of Macrolides. Clinical Pharmacokinetics, 2009, 48, 23-38.	3.5	29
122	Plasma protein binding of fluoroquinolones affects antimicrobial activity. Journal of Antimicrobial Chemotherapy, 2008, 61, 561-567.	3.0	44
123	Clinical Scoring System for the Prediction of Target Site Penetration of Antimicrobials in Patients with Sepsis. Clinical Pharmacokinetics, 2007, 46, 75-83.	3.5	13
124	Lung microdialysis—A powerful tool for the determination of exogenous and endogenous compounds in the lower respiratory tract (mini-review). AAPS Journal, 2005, 7, E600-E608.	4.4	50